Atrium Therapeutics Inc.
RNA | NASDAQ
$8.47
+$0.20 (+2.42%)
Nov 2, 2026, 11:21 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 |
|---|---|
Net Income | -49.5M |
Depreciation & Amortization | 323K |
Stock-Based Compensation | 7.68M |
Other Working Capital | -3.93M |
Other Non-Cash Items | 712K |
Deferred Income Tax | -142K |
Change in Working Capital | -200K |
Operating Cash Flow | -41.13M |
Capital Expenditures | -1.45M |
Cash Acquisitions | n/a |
Purchase of Investments | n/a |
Sales Maturities Of Investments | n/a |
Other Investing Acitivies | n/a |
Investing Cash Flow | -1.45M |
Debt Repayment | n/a |
Common Stock Repurchased | n/a |
Dividend Paid | n/a |
Other Financial Acitivies | 42.57M |
Financial Cash Flow | 42.57M |
Net Cash Flow | n/a |
Free Cash Flow | -42.57M |
Adj. Free Cash Flow | -50.25M |
Maintenance CapEx | -1.45M |
Growth CapEx | n/a |
Owner Earnings | -42.57M |
Add to Watchlist
Select watchlists to add or remove RNA